Olanzapine-induced Cataract in a Teenage Girl

Chang Zhen Lim¹, Khairy Shamel Sonny Teo¹, Evelyn Tai¹

¹. Ophthalmology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, MYS

Corresponding author: Evelyn Tai, daileid@yahoo.com

Abstract

Cataract, defined as cloudiness of the lens, is a common adverse effect of first-generation antipsychotic medications. Newer generation antipsychotics, also known as atypical antipsychotics, are less commonly associated with cataract. A 19-year-old girl with underlying schizophrenia on olanzapine for the past two years complained of gradual blurring of vision in both eyes for four months prior to presentation. On examination, the best corrected visual acuity was counting finger in both eyes. The anterior segment examination showed bilateral diffuse cortical cataract precluding fundus examination. Systemic examination was unremarkable. Blood investigations revealed a high random blood sugar, which normalised after she was initiated on oral hypoglycemic medication. After bilateral lens aspiration, her visual acuity was 6/6 bilaterally. Olanzapine may be cataractogenic via its action as a serotonin antagonist, which results in reduced glucose responsiveness of the pancreatic beta-cells. Patients on anti-psychotic medication are at risk of developing diabetes mellitus and cataract compared to the general population. Screening for diabetes mellitus should be part of the follow-up of these patients. Ophthalmological evaluation is warranted in the presence of visual complaints.

Categories: Endocrinology/Diabetes/Metabolism, Ophthalmology, Psychiatry

Keywords: olanzapine, schizophrenia, cataract, glucose intolerance, antipsychotic agents, diabetes mellitus

Introduction

Cataract is the main cause of reversible blindness and serious visual impairment worldwide. It is also notable as a side effect of typical antipsychotic drugs, mainly phenothiazines [1]. Although there is no direct etiological link between atypical antipsychotics and cataract formation, rare cases of cataract have been reported among patients on these medications [1]. We present a case of olanzapine-induced cataract in a teenage girl and discuss the underlying pathophysiology of this condition.

Case Presentation

A physically healthy 19-year-old schizophrenic girl on oral olanzapine 10 mg nightly for the past two years complained of bilateral progressive blurring of vision for four months. She denied any history of eye trauma, red eye, or eye pain. Besides that, she also had polydipsia and nocturia.

On examination, visual acuity was counting fingers at 1 m distance in both eyes. Anterior segment examination revealed bilateral diffuse cortical cataract (Figure 1) precluding fundus examination. Ultrasound B-scans of both eyes showed normal posterior segments.

FIGURE 1: Anterior segment of both eyes

Bilateral diffuse cortical cataract in (a) the right eye and (b) the left eye

Systemic workup revealed random blood sugar of 21 mmol/L and an HbA1C of 17.1 %. She was referred to an

Received 04/06/2018

Review began 04/12/2018

Review ended 04/28/2018

Published 04/30/2018

© Copyright 2018

Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

endocrinologist for initiation of treatment to stabilise her blood sugar. The psychiatrist in charge was alerted as well. Both disciplines agreed to substitute oral olanzapine for intra-muscular flupentixol. The patient was also started on oral anti-diabetic medication.

She underwent uneventful bilateral lens aspiration with intraocular lens implantation under general anaesthesia. After the surgery, her best corrected visual acuity was 6/6 in both eyes. She responded well to the new antipsychotic treatment and her blood sugar was well controlled on two types of oral anti-diabetic agents. On her last review, her blood sugar levels had normalised. The fundi were normal.

Discussion

Atypical antipsychotics are an integral part of schizophrenia management, both for clinical disease control and relapse prevention [2]. Although their side effect profile is more tolerable than their predecessors, potential ocular-associated complications include acute dystonia of extraocular muscles, ocular pigmentation, and cataract [1, 3]. The etiology of antipsychotic-induced cataract is poorly understood, but altered glucose homeostasis secondary to drug-mediated receptor interactions may play a role [4].

Olanzapine is an atypical antipsychotic which mediates its effects by serotonin-dopamine antagonism. It has been hypothesized that serotonin antagonism results in reduced glucose responsiveness of the pancreatic beta-cells [5-6]. This explains olanzapine's diabetogenic effect, as was observed in our patient. In diabetic patients, impaired glucose tolerance causes sorbitol accumulation in the lens via the polyol pathway, resulting in oxidative stress and cataract formation [7]. Besides that, non-enzymatic glycation of lens proteins may also contribute to formations of cataract [8]. Diabetic cataracts are characterised by diffuse subcapsular or cortical 'snowflake' opacities at the initial stage, later followed by generalized cortical cataract, as in our patient [9]. Cortical cataract has been found to be associated with diabetes mellitus regardless of glucose control [10].

Hyperglycemia has been observed as early as 10 days after initiation of olanzapine [6]. Although our patient had symptoms suggestive of a hyperglycemic state for the past few years, she was only diagnosed with diabetes during her pre-operative review. The cataract in our patient may thus be attributed to diabetes mellitus secondary to olanzapine.

Conclusions

Atypical antipsychotics are the mainstay of schizophrenia management. Cataract is an uncommon side effect of these medications and can occur due to impaired glucose tolerance. Ocular complaints among patients on antipsychotics warrants early ophthalmological and medical evaluation to allow timely treatment of potentially reversible conditions.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Souza VB, Moura Filho FJ, Souza FG, et al.: Cataract occurrence in patients treated with antipsychotic drugs . *Rev Bras Psiquiatr.* 2008, 30:222-226. [10.1590/s1516-44462008000300008](https://doi.org/10.1590/s1516-44462008000300008)
2. Leo RJ, Regno PD: Atypical antipsychotic use in the treatment of psychosis in primary care . *Prim Care Companion J Clin Psychiatry.* 2000, 2:194-204. [10.4088/PCC.v02n0601](https://doi.org/10.4088/PCC.v02n0601)
3. Rasimas JJ, Liebelt EL: Adverse effects and toxicity of the atypical antipsychotics: what is important for the pediatric emergency medicine practitioner. *Clin Pediatr Emerg Med.* 2012, 13:300-310. [10.1016/j.cpem.2012.09.005](https://doi.org/10.1016/j.cpem.2012.09.005)
4. Smith GC, Chaussade C, Vickers M, et al.: Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. *Diabetologia.* 2008, 51:2309-2317. [10.1007/s00125-008-1152-3](https://doi.org/10.1007/s00125-008-1152-3)
5. Bettinger TL, Mendelson SC, Dorson PG, et al.: Olanzapine-induced glucose dysregulation. *Ann Pharmacother.* 2000, 34:865-867. [10.1345/aph.19327](https://doi.org/10.1345/aph.19327)
6. Kumar PNS, Thomas B: Hyperglycemia associated with olanzapine treatment . *Indian J Psychiatry.* 2011, 53:176-177. [10.4103/0019-5545.82562](https://doi.org/10.4103/0019-5545.82562)
7. Lee AYW, Chung SSM: Contributions of polyol pathway to oxidative stress in diabetic cataract . *FASEB J.* 1999, 13:23-30. [10.1096/fasebj.13.1.23](https://doi.org/10.1096/fasebj.13.1.23)
8. Karasik A, Modan M, Halkin H, et al.: Senile cataract and glucose intolerance: the Israel study of glucose intolerance obesity and hypertension (the Israel GOH study). *Diabetes Care.* 1984, 7:52-56.

[10.2337/diacare.7.1.52](#)

9. Datta V, Swift PGF, Woodruff GHA, et al.: Metabolic cataracts in newly diagnosed diabetes . Arch Dis Child. 1997, 76:118-120. [10.1136/adc.76.2.118](#)
10. Olafsdottir E, Andersson DK, Stefansson E: The prevalence of cataract in a population with and without type 2 diabetes mellitus. Acta Ophthalmol. 2012, 90:334-340. [10.1111/j.1755-3768.2011.02326.x](#)